Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 5 art units • 6 examiners • 0 of 8 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
University of Leicester has 8 pending office actions in Biotechnology & Pharmaceuticals. The matters span 6 distinct examiners and 5 distinct art units, showing that the portfolio extends across multiple examination relationships and technical assignments. The distribution calls for coordinated docket control alongside separate review of examiner practice and art-unit requirements.
SKELDING, ZACHARY S is the busiest examiner, with 3 pending actions. That examiner accounts for a defined concentration of the pending work, while the remaining matters are distributed among other examiners. Counsel may benefit from grouping responses involving the same examiner, while maintaining distinct claim and prior-art analyses for matters assigned elsewhere.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (12%) |
| §103 only | 2 (25%) |
| §112 only | 1 (12%) |
| Double-patenting + other | 2 (25%) |
| Multi-statute (no §101) | 2 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SKELDING, ZACHARY S | 3 | 59.8% | +41.1% |
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
| JOHNSON, CHRISTOPHER LINDSAY | 1 | 48.6% | +78.3% |
| BENAVIDES, JENNIFER ANN | 1 | 50.8% | +47.3% |
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| STONEBRAKER, ALYSSA RAE | 1 | 58.9% | +49.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18355871 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | SKELDING, ZACHARY S | 69d |
| 18290241 | VINYL ISOCYANIDE COMPOUNDS AS ANTIBACTERIAL AGENTS | JOHNSON, CHRISTOPHER LINDSAY | — |
| 17794214 | HDAC Degrader | O DELL, DAVID K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18355871 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | SKELDING, ZACHARY S | 69d |
| 17498521 | Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria | STONEBRAKER, ALYSSA RAE | 76d |
| 18633379 | METHODS FOR INHIBITING ANGIOGENESIS IN A SUBJECT IN NEED THEREOF | WANG, CHANG YU | — |
| 18290241 | VINYL ISOCYANIDE COMPOUNDS AS ANTIBACTERIAL AGENTS | JOHNSON, CHRISTOPHER LINDSAY | — |
| 18474631 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | SKELDING, ZACHARY S | — |
| 18312891 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | SKELDING, ZACHARY S | — |
| 18051993 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | BENAVIDES, JENNIFER ANN | — |
| 17794214 | HDAC Degrader | O DELL, DAVID K | — |
| Art Unit | Apps |
|---|---|
| 1644 | 3 |
| 1675 | 2 |
| 1691 | 1 |
| 1621 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18633379 | METHODS FOR INHIBITING ANGIOGENESIS IN A SUBJECT IN NEED THEREOF | WANG, CHANG YU | 1675 | §102§112DP | Non-Final OA | — | Pending | Apr 11, 2024 |
| 18290241 | VINYL ISOCYANIDE COMPOUNDS AS ANTIBACTERIAL AGENTS | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §101§112 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18474631 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | SKELDING, ZACHARY S | 1644 | §103 | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18355871 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | SKELDING, ZACHARY S | 1644 | §102§103§112 | Non-Final OA | 69d | Pending | Jul 20, 2023 |
| 18312891 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | SKELDING, ZACHARY S | 1644 | §103 | Non-Final OA | — | Pending | May 05, 2023 |
| 18051993 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | BENAVIDES, JENNIFER ANN | 1675 | §103DP | Final Rejection | — | Pending | Nov 02, 2022 |
| 17794214 | HDAC Degrader | O DELL, DAVID K | 1621 | §103§112 | Non-Final OA | — | Pending | Jul 20, 2022 |
| 17498521 | Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria | STONEBRAKER, ALYSSA RAE | 1642 | §112Other | Non-Final OA | 76d | Pending | Oct 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversity of Leicester has 8 pending office actions as of October 2026, spread across 5 art units and 6 examiners.
Zachary S Skelding has the most, with 3 of University of Leicester's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
